老年人慢性肾脏病：初级保健提供者面临的挑战和机遇。
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider.
机构信息
Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Medicine, Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
出版信息
BMC Prim Care. 2024 Nov 1;25(1):388. doi: 10.1186/s12875-024-02638-4.
Abstract
Kidney disease and its comorbidities disproportionately affect older persons. Kidney disease modifying therapy is underutilized in older adults, as guidelines lack consensus on approaching diagnosis and treatment in older adults. This review aims to highlight the challenges presented by, and opportunities for, identifying and treating CKD in older adults.
摘要
肾脏疾病及其合并症在老年人中不成比例地发生。肾脏疾病的治疗方法在老年人中未得到充分利用，因为指南在老年人的诊断和治疗方法上缺乏共识。本综述旨在强调在老年人中识别和治疗 CKD 所面临的挑战和机遇。
相似文献
1
Chronic kidney disease in older adults: challenges and opportunities for the primary care provider.老年人慢性肾脏病：初级保健提供者面临的挑战和机遇。
BMC Prim Care. 2024 Nov 1;25(1):388. doi: 10.1186/s12875-024-02638-4.
2
Integrating guidelines, CKD, multimorbidity, and older adults.整合指南、慢性肾脏病、多种疾病及老年人。
Am J Kidney Dis. 2015 Mar;65(3):494-501. doi: 10.1053/j.ajkd.2014.09.024. Epub 2014 Dec 4.
3
[What do we know about chronic kidney disease at the beginning of the 21st century?].在21世纪初，我们对慢性肾脏病了解多少？
Acta Med Croatica. 2014 Apr;68(2):75-7.
4
Barriers and enablers to detection and management of chronic kidney disease in primary healthcare: a systematic review.基层医疗中慢性肾脏病的检测和管理的障碍和促进因素：系统评价。
BMC Nephrol. 2020 Mar 12;21(1):83. doi: 10.1186/s12882-020-01731-x.
5
Mild chronic kidney disease and functional impairment in community-dwelling older adults.社区居住的老年人中轻度慢性肾脏病和功能障碍。
Age Ageing. 2013 Jul;42(4):488-94. doi: 10.1093/ageing/aft007. Epub 2013 Feb 24.
6
Development and Validation of the Rating of CKD Knowledge Among Older Adults (Know-CKD) With Kidney Failure.慢性肾脏病老年人知识评分量表（Know-CKD）在肾衰竭患者中的制定与验证。
Am J Kidney Dis. 2024 May;83(5):569-577. doi: 10.1053/j.ajkd.2023.09.024. Epub 2023 Dec 7.
7
Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data.基层医疗患者贫血与慢性肾脏病的关联：慢性肾脏病质量改进（QICKD）试验数据的横断面研究。
BMC Nephrol. 2013 Jan 25;14:24. doi: 10.1186/1471-2369-14-24.
8
A population-based cohort study defines prognoses in severe chronic kidney disease.一项基于人群的队列研究定义了严重慢性肾脏病的预后。
Kidney Int. 2018 May;93(5):1217-1226. doi: 10.1016/j.kint.2017.12.013. Epub 2018 Mar 7.
9
Primary care physicians' perceived barriers, facilitators and strategies to enhance conservative care for older adults with chronic kidney disease: a qualitative descriptive study.基层医疗医生对加强老年慢性肾脏病患者保守治疗的认知障碍、促进因素及策略：一项定性描述性研究
Nephrol Dial Transplant. 2016 Nov;31(11):1864-1870. doi: 10.1093/ndt/gfv408. Epub 2015 Dec 17.
10
Epidemiology and Public Health Concerns of CKD in Older Adults.老年慢性肾脏病的流行病学及公共卫生问题
Adv Chronic Kidney Dis. 2016 Jan;23(1):8-11. doi: 10.1053/j.ackd.2015.10.001.
本文引用的文献
1
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.达格列净在慢性肾脏病各年龄段和不同性别中的影响。
J Gen Intern Med. 2024 May;39(6):921-930. doi: 10.1007/s11606-023-08397-9. Epub 2023 Dec 14.
2
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
3
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.达格列净在慢性肾脏病各虚弱谱患者中的疗效和安全性。
J Gerontol A Biol Sci Med Sci. 2024 Feb 1;79(2). doi: 10.1093/gerona/glad181.
4
Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease.美国慢性肾脏病风险成人白蛋白尿的估计患病率和检测情况。
JAMA Netw Open. 2023 Jul 3;6(7):e2326230. doi: 10.1001/jamanetworkopen.2023.26230.
5
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.卡格列净对年龄和性别的肾脏和心血管影响：CREDENCE 随机临床试验的事后分析。
Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7.
6
US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United States.美国肾脏数据系统2022年年报：美国肾脏疾病流行病学
Am J Kidney Dis. 2023 Mar;81(3 Suppl1):A8-A11. doi: 10.1053/j.ajkd.2022.12.001.
7
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.预测因素、差异和医疗机构间的差异：美国慢性肾脏病退伍军人中 SGLT2 抑制剂的处方情况。
Am J Kidney Dis. 2023 Jul;82(1):53-62.e1. doi: 10.1053/j.ajkd.2022.11.017. Epub 2023 Jan 23.
8
Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.影响香港 2 型糖尿病伴心血管疾病/慢性肾脏病患者开具钠-葡萄糖共转运蛋白 2 抑制剂处方的因素：一项定性研究。
BMC Prim Care. 2022 Dec 7;23(1):317. doi: 10.1186/s12875-022-01928-z.
9
Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease.钠-葡萄糖协同转运蛋白 2 抑制剂和肾素-血管紧张素系统抑制剂在糖尿病肾病患者处方中的空白。
J Gen Intern Med. 2023 May;38(7):1599-1605. doi: 10.1007/s11606-022-07863-0. Epub 2022 Nov 9.
10
Empagliflozin in Patients with Chronic Kidney Disease.恩格列净在慢性肾脏病患者中的应用。
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
Zotero 插件